OPRT Oportun beats Q4 2025 EPS estimates by 103 percent shares gain 191 percent in todays session Is Tarsus Pharmaceuticals TARS stock failing to hold levels Tarsus Pharmaceuticals posts wider than expected EPS loss Global AI Sector Disruption and US Market Reaction Following DeepSeek R1 Launch Does MKDWELL MKDW stock justify its valuation US March 2024 Retail Sales Analysis Amid Geopolitical Energy Shocks